Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Average Price Target of $23.36

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) have been assigned an average recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $23.36.

Several research analysts recently issued reports on CMPS shares. Morgan Stanley raised their target price on shares of Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. BTIG Research raised their price objective on shares of Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Evercore raised shares of Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 target price for the company in a report on Wednesday, July 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research note on Thursday, October 15th. Finally, Wells Fargo & Company initiated coverage on shares of Compass Pathways in a report on Monday, July 27th. They set an “equal weight” rating and a $13.00 price target on the stock.

Compass Pathways Price Performance

CMPS opened at $11.57 on Monday. Compass Pathways has a 1 year low of $4.88 and a 1 year high of $15.87. The business’s 50-day moving average is $12.91 and its two-hundred day moving average is $10.38. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30. The firm has a market capitalization of $1.60 billion, a PE ratio of -2.50 and a beta of 2.55.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). Research analysts anticipate that Compass Pathways will post -1.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Integrity Alliance LLC. acquired a new position in shares of Compass Pathways in the third quarter worth $128,000. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Compass Pathways by 23.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 399,506 shares of the company’s stock worth $4,970,000 after buying an additional 76,297 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Compass Pathways during the 3rd quarter worth about $85,000. China Universal Asset Management Co. Ltd. increased its position in shares of Compass Pathways by 15.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 24,432 shares of the company’s stock worth $317,000 after acquiring an additional 3,249 shares in the last quarter. Finally, North Star Investment Management Corp. lifted its stake in shares of Compass Pathways by 23.9% during the third quarter. North Star Investment Management Corp. now owns 9,317 shares of the company’s stock worth $116,000 after purchasing an additional 1,800 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.